Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands—Results From the MPOWERED Trial

Background: Patients with acromegaly may have high symptom burden. The phase 3 MPOWERED trial assessed control of acromegaly by oral octreotide capsules (OOC; MYCAPSSA(®)) in comparison to injectable somatostatin receptor ligands (iSRLs) in patients responding to both OOC and iSRLs. iSRLs have been...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Endocr Soc
Glavni autori: Biermasz, Nienke, Fleseriu, Maria, Dreval, Akexander V, Pokramovich, Yulia, Bondar, Irina, Isaeva, Elena, Molitch, Mark E, Macut, Djuro P, Leonova, Nina, Raverot, Gerald, Gilgun-Sherki, Yossi, Ludlam, William H, Patou, Gary, Haviv, Asi, Gordon, Murray B, Urbanavicius, Vaidotas, Knispelis, Robertas, Melmed, Shlomo, Strasburger, Christian J
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2021
Teme:
Neuroendocrinology and Pituitary
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8090610/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1065
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items